The Foundry Announces Successful First-In-Human Procedure In Study Of Innovative Transcatheter Mitral Valve Repair Technology

The Foundry today announced the successful completion of the first-in-human procedure with the Half Moon Medical transcatheter mitral repair technology (TMVr) at Oregon Health and Science University (OHSU) as part of an FDA-approved early feasibility study. The first patient treated has been discharged from the hospital and is recovering as expected.

The investigational Half Moon mitral valve repair device, developed through a unique partnership between Medtronic (NYSE:MDT) and The Foundry, is designed to restore function in a diseased mitral valve in patients with severe symptomatic mitral regurgitation (MR), a disease where blood leaks backwards within the heart due to the mitral valve's inability to close properly.

"We are pleased to be able to offer our patients new options for heart valve repair as early as possible through studies such as this," said Firas Zahr , M.D., OHSU interventional cardiology director, who co-led the procedure.

"Minimally invasive transcatheter heart valve repair can offer relief from mitral valve regurgitation without the need for traditional open-heart surgery," said Howard Song , M.D., Ph.D., OHSU cardiothoracic surgery division chief, who co-led the procedure. Scott Chadderdon , M.D., OHSU Knight Cardiovascular Institute clinical trials director, also led echocardiography to guide the procedure.

The Half Moon mitral valve repair device is unique from other mitral valve repair technologies in maintaining more natural physiologic functionality of the mitral valve. It is deployed using a transfemoral (through the leg) delivery catheter, which is navigated through the vasculature to the diseased native mitral valve. The device is fully repositionable and recoverable during deployment and preserves options for patients who may need re-intervention in the future.

"This technology is a truly innovative solution designed to eliminate regurgitation by restoring physiologic coaptation of the native mitral valve," said Matt McLean , Co-Founder and Chief Operating Officer at Half Moon Medical, the sixteenth Foundry company, founded in 2017. "On behalf of the entire team at Half Moon, I would like to congratulate the team at OHSU on this incredible achievement."

Mitral regurgitation is the most common heart valve disease in the US, affecting an estimated four million people. If left untreated, MR may lead to chronic heart failure, the leading cause of hospitalization in the U.S. and Europe .

About The Foundry
The Foundry was founded in 1998 to rapidly translate concepts into successful new medical device companies. In addition to inventing new technologies itself, The Foundry works closely with outside inventors with promising ideas. Over the past 22 years, The Foundry has formed over 22 new companies, including Evalve (Abbott- MitraClip) and Twelve (Medtronic- Intrepid) in the structural heart space. Other companies include Concentric Medical (acquired by Stryker), Emphasys (acquired by Pulmonx), Ardian (acquired by Medtronic), and incubator Forsight Labs, which has created several successful ophthalmic companies. The Foundry, LLC is located in Menlo Park, California . For more information, visit the company's website at www.thefoundry.com .

Contacts:

Katy Frame
(610)-613-3549
kframe@brgcommunications.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/the-foundry-announces-successful-first-in-human-procedure-in-study-of-innovative-transcatheter-mitral-valve-repair-technology-301204824.html

SOURCE The Foundry

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company") is pleased to announce it will be recognized on The Globe and Mail's 2024 Report on Business magazine's fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity.

The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks. The ranked companies have made tangible and organizational progress related to executive gender parity.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

  • Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023
  • Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue ® Sirolimus AngioInfusion TM Balloon ("SAB") development and commercialization for treatment of coronary and peripheral artery disease
  • Expected runway of cash and cash equivalents and marketable securities, including certain potential future proceeds sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

"2023 was a year of strong momentum for Orchestra BioMed as we made significant progress on our cardiovascular pipeline with the achievement of key regulatory milestones and completion of our successful Nasdaq listing," commented David Hochman, chairman, chief executive officer and founder of Orchestra BioMed. "In December, we initiated the BACKBEAT global pivotal study evaluating our lead program, AVIM therapy, in hypertensive pacemaker patients working alongside our strategic partner Medtronic, the global market leader in cardiac pacing therapies. We see a substantial market opportunity for AVIM therapy in this patient population, as well as in other high-risk hypertension populations."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Peer-Review Further Supports CLEO’s Ovarian Cancer Detection Technology

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of further data on its triage test for ovarian cancer.

Keep reading...Show less

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×